Physician profile
Ned D Freeman
NPI 1578555173
$9,981.70
in general payments reported to CMS, 2019-2025
38 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,979 · 2020: $942 · 2021: $2,096 · 2022: $2,115 · 2023: $734 · 2024: $761 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,329.35 | 2019-2024 | Xarelto |
| Amgen INC. | $1,409.31 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $892.38 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $820.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $671.79 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $568.38 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $554.87 | 2021-2025 | |
| Pfizer INC. | $411.91 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $401.90 | 2019-2024 | |
| Amarin Pharma, INC. | $273.30 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $239.55 | 2019-2025 | Camzyos |
| Gilead Sciences, INC. | $226.75 | 2019 | |
| Biosense Webster, INC. | $160.19 | 2021 | |
| Lundbeck LLC | $124.57 | 2019 | |
| Edwards Lifesciences Corporation | $111.09 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ned Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.